ErbB 4 Blocking Peptide peptide (STJ504219)

SKU:
STJ504219-250

Shipping:
Free Shipping
Current Stock:
Applications: Immunodepletion/Immunocompetition
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: ErbB 4 Blocking Peptide is synthetically produced from the 1225-1275 sequence and is suitable for use in western blot applications.
Formulation: Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice.
Storage Instruction: Store at-20°C for long term storage. Avoid freeze-thaw cycles.
Gene Symbol: ERBB4
Gene ID: 2066
Uniprot ID: ERBB4_HUMAN
Immunogen Region: 1225-1275
Immunogen: Synthetic peptide taken within amino acid region 1225-1275 on human Receptor tyrosine-protein kinase erbB-4.
Tissue Specificity Expressed at highest levels in brain, heart, kidney, in addition to skeletal muscle, parathyroid, cerebellum, pituitary, spleen, testis and breast. Lower levels in thymus, lung, salivary gland, and pancreas. Isoform JM-A CYT-1 and isoform JM-B CYT-1 are expressed in cerebellum, but only the isoform JM-B is expressed in the heart.
Post Translational Modifications Isoform JM-A CYT-1 and isoform JM-A CYT-2 are processed by ADAM17. Proteolytic processing in response to ligand or 12-O-tetradecanoylphorbol-13-acetate stimulation results in the production of 120 kDa soluble receptor forms and intermediate membrane-anchored 80 kDa fragments (m80HER4), which are further processed by a presenilin-dependent gamma-secretase to release a cytoplasmic intracellular domain (E4ICD.E4ICD1/s80Cyt1 or E4ICD2/s80Cyt2, depending on the isoform). Membrane-anchored 80 kDa fragments of the processed isoform JM-A CYT-1 are more readily degraded by the proteasome than fragments of isoform JM-A CYT-2, suggesting a prevalence of E4ICD2 over E4ICD1. Isoform JM-B CYT-1 and isoform JM-B CYT-2 lack the ADAM17 cleavage site and are not processed by ADAM17, precluding further processing by gamma-secretase. Autophosphorylated on tyrosine residues in response to ligand binding. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit. Ligands trigger phosphorylation at specific tyrosine residues, thereby creating binding sites for scaffold proteins and effectors. Constitutively phosphorylated at a basal level when overexpressed in heterologous systems.ligand binding leads to increased phosphorylation. Phosphorylation at Tyr-1035 is important for interaction with STAT1. Phosphorylation at Tyr-1056 is important for interaction with PIK3R1. Phosphorylation at Tyr-1242 is important for interaction with SHC1. Phosphorylation at Tyr-1188 may also contribute to the interaction with SHC1. Isoform JM-A CYT-2 is constitutively phosphorylated on tyrosine residues in a ligand-independent manner. E4ICD2 but not E4ICD1 is phosphorylated on tyrosine residues. Ubiquitinated. During mitosis, the ERBB4 intracellular domain is ubiquitinated by the APC/C complex and targeted to proteasomal degradation. Isoform JM-A CYT-1 and isoform JM-B CYT-1 are ubiquitinated by WWP1. The ERBB4 intracellular domain (E4ICD1) is ubiquitinated, and this involves NEDD4.
Function Tyrosine-protein kinase that plays an essential role as cell surface receptor for neuregulins and EGF family members and regulates development of the heart, the central nervous system and the mammary gland, gene transcription, cell proliferation, differentiation, migration and apoptosis. Required for normal cardiac muscle differentiation during embryonic development, and for postnatal cardiomyocyte proliferation. Required for normal development of the embryonic central nervous system, especially for normal neural crest cell migration and normal axon guidance. Required for mammary gland differentiation, induction of milk proteins and lactation. Acts as cell-surface receptor for the neuregulins NRG1, NRG2, NRG3 and NRG4 and the EGF family members BTC, EREG and HBEGF. Ligand binding triggers receptor dimerization and autophosphorylation at specific tyrosine residues that then serve as binding sites for scaffold proteins and effectors. Ligand specificity and signaling is modulated by alternative splicing, proteolytic processing, and by the formation of heterodimers with other ERBB family members, thereby creating multiple combinations of intracellular phosphotyrosines that trigger ligand- and context-specific cellular responses. Mediates phosphorylation of SHC1 and activation of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Isoform JM-A CYT-1 and isoform JM-B CYT-1 phosphorylate PIK3R1, leading to the activation of phosphatidylinositol 3-kinase and AKT1 and protect cells against apoptosis. Isoform JM-A CYT-1 and isoform JM-B CYT-1 mediate reorganization of the actin cytoskeleton and promote cell migration in response to NRG1. Isoform JM-A CYT-2 and isoform JM-B CYT-2 lack the phosphotyrosine that mediates interaction with PIK3R1, and hence do not phosphorylate PIK3R1, do not protect cells against apoptosis, and do not promote reorganization of the actin cytoskeleton and cell migration. Proteolytic processing of isoform JM-A CYT-1 and isoform JM-A CYT-2 gives rise to the corresponding soluble intracellular domains (4ICD) that translocate to the nucleus, promote nuclear import of STAT5A, activation of STAT5A, mammary epithelium differentiation, cell proliferation and activation of gene expression. The ERBB4 soluble intracellular domains (4ICD) colocalize with STAT5A at the CSN2 promoter to regulate transcription of milk proteins during lactation. The ERBB4 soluble intracellular domains can also translocate to mitochondria and promote apoptosis.
Peptide Name Receptor Tyrosine-Protein Kinase Erbb-4
Proto-Oncogene-Like Protein C-Erbb-4
Tyrosine Kinase-Type Cell Surface Receptor Her4
P180erbb4 Cleaved Into - Erbb4 Intracellular Domain
4icd
E4icd
S80her4
Database Links Reactome: R-HSA-1227986
Reactome: R-HSA-1236394
Reactome: R-HSA-1250196
Reactome: R-HSA-1250342
Reactome: R-HSA-1250347
Reactome: R-HSA-1251985
Reactome: R-HSA-1253288
Reactome: R-HSA-1257604
Reactome: R-HSA-1963640
Reactome: R-HSA-1963642
Reactome: R-HSA-2219530
Reactome: R-HSA-5673001
Reactome: R-HSA-6785631
Reactome: R-HSA-6811558
Reactome: R-HSA-8847993
Reactome: R-HSA-8863795
Reactome: R-HSA-9018519
Reactome: R-HSA-9620244
Reactome: R-HSA-9664565
Reactome: R-HSA-9665686
Cellular Localisation Cell Membrane
Single-Pass Type I Membrane Protein
In Response To Nrg1 Treatment
The Activated Receptor Is Internalized
Erbb4 Intracellular Domain: Nucleus
Mitochondrion
Following Proteolytical Processing E4icd (E4icd1 Or E4icd2 Generated From The Respective Isoforms) Is Translocated To The Nucleus
Significantly More E4icd2 Than E4icd1 Is Found In The Nucleus
E4icd2 Colocalizes With Yap1 In The Nucleus
Alternative Peptide Names Receptor Tyrosine-Protein Kinase Erbb-4 protein
Proto-Oncogene-Like Protein C-Erbb-4 protein
Tyrosine Kinase-Type Cell Surface Receptor Her4 protein
P180erbb4 Cleaved Into - Erbb4 Intracellular Domain protein
4icd protein
E4icd protein
S80her4 protein
ERBB4 protein
HER4 protein

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance